- Home
- XAIR vs BIVI Comparison
XAIR vs BIVI Comparison
Compare XAIR & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- BIVI
- Stock Information
- Founded
- XAIR 2011
- BIVI 2013
- Country
- XAIR United States
- BIVI United States
- Employees
- XAIR N/A
- BIVI N/A
- Industry
- XAIR Medical/Dental Instruments
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- XAIR Health Care
- BIVI Health Care
- Exchange
- XAIR Nasdaq
- BIVI Nasdaq
- Market Cap
- XAIR 17.0M
- BIVI 18.6M
- IPO Year
- XAIR N/A
- BIVI N/A
- Fundamental
- Price
- XAIR $0.22
- BIVI $1.04
- Analyst Decision
- XAIR Buy
- BIVI Strong Buy
- Analyst Count
- XAIR 3
- BIVI 1
- Target Price
- XAIR $1.50
- BIVI $30.00
- AVG Volume (30 Days)
- XAIR 4.9M
- BIVI 196.4K
- Earning Date
- XAIR 06-17-2025
- BIVI 05-12-2025
- Dividend Yield
- XAIR N/A
- BIVI N/A
- EPS Growth
- XAIR N/A
- BIVI N/A
- EPS
- XAIR N/A
- BIVI N/A
- Revenue
- XAIR $3,705,000.00
- BIVI N/A
- Revenue This Year
- XAIR $286.75
- BIVI N/A
- Revenue Next Year
- XAIR $144.39
- BIVI N/A
- P/E Ratio
- XAIR N/A
- BIVI N/A
- Revenue Growth
- XAIR 219.67
- BIVI N/A
- 52 Week Low
- XAIR $0.16
- BIVI $0.62
- 52 Week High
- XAIR $1.49
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- XAIR 55.40
- BIVI 50.59
- Support Level
- XAIR $0.17
- BIVI $1.01
- Resistance Level
- XAIR $0.29
- BIVI $1.11
- Average True Range (ATR)
- XAIR 0.02
- BIVI 0.07
- MACD
- XAIR 0.01
- BIVI -0.01
- Stochastic Oscillator
- XAIR 46.03
- BIVI 34.95
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.